Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed [0.03%]
新型降低低密度脂胆固醇疗法用于动脉粥样硬化性心血管疾病的一级预防——探索他人未及的靶点达标路径
Artur Dziewierz,Beata Bobrowska,Witold Streb et al.
Artur Dziewierz et al.
Introduction: Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of global morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) established as a primary causal factor. Des...
How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease? [0.03%]
胆固醇流出能力可作为动脉粥样硬化性心血管疾病的危险因素吗？
Masatsune Ogura
Masatsune Ogura
Introduction: High-density lipoprotein cholesterol (HDL-C) has long been regarded as 'good cholesterol,' but clinical trials and epidemiological studies have demonstrated that simply raising HDL-C levels does not reduce c...
Alternative options to thermal ablation for atrial fibrillation: the role of pulsed field ablation in reducing complications and maintaining efficacy [0.03%]
用于房颤治疗的射频消融替代方法：脉冲电场消融减少并发症和维持有效性的角色
Elio Zito,Vincenzo Mirco La Fazia,Carola Gianni et al.
Elio Zito et al.
Introduction: Catheter ablation has traditionally been performed using thermal modalities, which, despite being effective, remain associated with potentially severe complications such as pulmonary vein stenosis and atrioe...
Defining persistent atrial fibrillation patient subgroups: predicting responses to repeat ablation procedures to enhance treatment efficacy [0.03%]
房颤患者亚组的定义：预测重复射频消融术的疗效以提高治疗效果
Neil Bodagh,Kyaw Soe Tun,Mark O&#x;Neill et al.
Neil Bodagh et al.
Anti-inflammatory strategies for patients with atherosclerotic coronary disease [0.03%]
动脉粥样硬化性冠状动脉疾病患者的抗炎策略
Antonino Imbesi,Antonio Greco,Davide Capodanno
Antonino Imbesi
Introduction: Atherosclerosis, the primary cause of coronary artery disease (CAD), progresses through subclinical, chronic, and acute phases, culminating in acute myocardial infarction (AMI). Historically viewed as a lipi...
Reviewing the use of antiarrhythmic drugs in elderly patients with atrial fibrillation [0.03%]
老年房颤患者抗心律失常药物应用的再评价
Danilo Menichelli,Gianluca Gazzaniga,Daniele Malatesta et al.
Danilo Menichelli et al.
Introduction: Atrial fibrillation (AF) is the most common arrhythmia in elderly patients. Antiarrhythmic drugs (AADs) are often required for rate/rhythm control and to improve AF-related symptoms. There is limited evidenc...
What impact could tirzepatide have on major cardiovascular complications in patients with obstructive sleep apnea? [0.03%]
tirzepatide对阻塞性睡眠呼吸暂停患者主要心血管并发症的影响会是什么？
Avnee J Kumar,Samantha Scroggie,Tia De Sarkar et al.
Avnee J Kumar et al.
The role of stress-induced hyperglycemia in acute coronary syndromes: pathophysiology, novel markers and clinical implications [0.03%]
应激性高血糖在急性冠脉综合征中的作用：病理生理、新型标记物及临床意义
Marios G Bantidos,Nikolaos Stalikas,Barbara Fyntanidou et al.
Marios G Bantidos et al.
Introduction: Stress-Induced Hyperglycemia (SIH) represents a transient increase in blood glucose levels triggered by acute physiological stress, frequently observed in patients with Acute Coronary Syndrome (ACS). It is l...
Are antibiotic-eluting envelopes the solution to cardiac implantable electronic device infections? [0.03%]
抗生素缓释包膜是心脏植入型电子设备感染的解决方案吗？
Vassil Traykov
Vassil Traykov
The staging of cardiac damage for mitral regurgitation: ready for prime time? [0.03%]
二尖瓣反流心脏损害分期评定：时机已成熟？
Michail Penteris,Anastasia Kalogirou,Konstantinos Lampropoulos
Michail Penteris
Introduction: Mitral regurgitation (MR) is a progressive valvular heart disease (VHD) with significant morbidity and mortality, particularly in older adults. Current guidelines rely primarily on symptom status and LV func...